<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287118</url>
  </required_header>
  <id_info>
    <org_study_id>25161</org_study_id>
    <secondary_id>CONTROL I Study</secondary_id>
    <nct_id>NCT00287118</nct_id>
  </id_info>
  <brief_title>A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Patients With Moderate to Severe Plaque Psoriasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      Phase IIIb, open-label, multi-centre study to establish psoriasis control of moderate to
      severe plaque psoriasis with Raptiva therapy administered SC for 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving or maintaining a PGA (Physician Global Assessment) 7 points score, rated Excellent, or Cleared at week 24.</measure>
    <time_frame>PGA, PASI, DLQI, PSSI, PPASI to be collected at baseline, weeks 4, 8, 12, and 24 or early termination</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Candidates for Systemic Therapy for Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efalizumab=Raptiva</intervention_name>
    <description>Each patient will receive an initial conditioning dose of 0.7 mg/kg/week followed by 1.0 mg/kg/week study drug during the treatment period, 23 weeks. If four or more consecutive doses have been missed, dosing should resume with the conditioning dose of 0.7 mg/kg and then continue receiving 1mg/kg/week thereafter. Study drug will be administered by SC injection.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A)In the opinion of the investigator, candidate for systemic therapy for psoriasis
             could include:

          -  Patients with moderate to severe plaque psoriasis defined by PASI &gt;10 and BSA&gt;10-

          -  Patients with the following may also be deemed to require systemic therapy in the
             judgement of the physician:

          -  Severe psychosocial disability (in the judgement of the physician),or - Nail
             psoriasis, or

          -  Scalp psoriasis, or

          -  Palmar plantar psoriasis etc OR

          -  B)Subjects who have completed the CLEAR study IMP 24011 and who wish to continue
             Raptiva (efalizumab) therapy.

          -  Body weight of 120 kg

          -  18 to 75 years old

          -  For women of childbearing potential and for men whose partner can become pregnant,
             use of an acceptable method of contraception to prevent pregnancy and agreement to
             continue to practice an acceptable method of contraception for the duration of their
             participation in the study up to 3 months after the last dose of Raptiva

          -  Willingness to hold sun exposure reasonably constant and to avoid use of tanning
             booths or other UV light sources during the study

          -  Agreement to participate in the study

          -  Signed informed consent

          -  Discontinuation of any systemic psoriasis treatment prior to commencement of the
             study drug. No washout period is required for these agents prior to starting study
             and receiving first dose of study drug (Raptiva)

          -  Discontinuation of all biologic agents (other than Raptiva) 3 months prior to
             receiving first dose of study drug (Raptiva)

          -  Discontinuation of PUVA, UVB treatment 28 days prior to commencement of receiving
             first dose of study drug.

          -  Discontinuation of any investigational drug or treatment 3 months prior to study day
             0 or as per washout requirements from previous protocol

          -  No vaccinations (e.g., tetanus, booster, influenza vaccine) at least 14 days prior to
             first dose of study drug

          -  Treatment regimens of b blockers, ACE inhibitors, antimalarial drugs, quinidine,
             interferon, or lithium stable for at least 28 days prior to first dose of study drug
             (SD 0)

        Exclusion Criteria:

          -  Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of
             psoriasis

          -  Active rebound of psoriasis during or following discontinuation of the previous
             Raptiva treatment( PASI &gt;125% from baseline and/or new predominant morphology of
             psoriasis) when reason was adverse event or lack of efficacy of Raptiva. If it was
             due to another non drug reason (vaccination , or infection) then the patient can be
             included in this study.

          -  History of severe allergic or anaphylactic reactions to humanised monoclonal
             antibodies

          -  History of or ongoing uncontrolled bacterial, viral, fungal, or atypical
             mycobacterial infection

          -  History of opportunistic infections (e.g., systemic fungal infections, parasites)

          -  Seropositivity for human immunodeficiency virus (HIV). Patients will undergo
             mandatory testing at screening. Patients who are positive for HIV will be excluded.

          -  Pregnancy or lactation

          -  WBC count &lt;4000/L or &gt;14,000/L

          -  Patient with a history of clinically significant thrombocytopenia, bleeding disorders
             or a platelet count &lt; 100,000 cells/L

          -  Seropositivity for hepatitis B or C virus Patients will undergo testing at screening.
             Patients who are positive for hepatitis B antigen or hepatitis C antibody will be
             excluded.

          -  Hepatic enzymes&gt; 3 times the upper limit of normal

          -  History of active tuberculosis (TB) or currently undergoing treatment for TB within
             one year prior to study day 0. Chest X-ray (within 3 months prior to SD0) is required
             for high-risk patients (appendix J). Patients with a positive chest X-ray will be
             excluded.

          -  Presence of malignancy within the past 5 years, including lymphoproliferative
             disorders. Patients with a history of fully resolved basal cell or squamous cell skin
             cancer may be enrolled.

          -  Diagnosis of hepatic cirrhosis, regardless of cause or severity

          -  Serum creatinine &gt;2 times the upper limit of normal

          -  Hospital admission for cardiac disease, stroke, or pulmonary disease within the last
             year

          -  History of substance abuse within the last 5 years

          -  Any medical condition that, in the judgment of the investigator, would jeopardize the
             patient's safety following exposure to study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiana Licu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Information Switzerland</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Stengel FM, Petri V, Campbell GA, Dorantes GL, LÃ³pez M, Galimberti RL, Valdez RP, de Arruda LF, Guerra MA, Chouela EN, Licu D; International IMP25161 Study Group.. Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results. Arch Drug Inf. 2009 Dec;2(4):71-78.</citation>
    <PMID>20098510</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>November 4, 2016</lastchanged_date>
  <firstreceived_date>February 2, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
